314 related articles for article (PubMed ID: 27063754)
21. Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy with and without Seasonal Dose Adjustment.
Albuhairi S; Sare T; Lakin P; El Khoury K; Crestani E; Schneider LC; Anzaldi R; Patterson A; Rachid R
J Allergy Clin Immunol Pract; 2018; 6(5):1711-1716.e4. PubMed ID: 29339129
[TBL] [Abstract][Full Text] [Related]
22. Local and systemic reactions to subcutaneous allergen immunotherapy: Ten years' experience in a pediatric clinic.
Nacaroglu HT; Erdem SB; Sumer O; Karaman S; Unsal Karkıner CS; Asilsoy S; Gunay I; Can D
Ann Allergy Asthma Immunol; 2016 Apr; 116(4):349-53. PubMed ID: 26905639
[TBL] [Abstract][Full Text] [Related]
23. Subcutaneous immunotherapy in Northern Israel: efficacy and safety.
Rottem M; Egbarya A
Isr Med Assoc J; 2014 Sep; 16(9):539-43. PubMed ID: 25351009
[TBL] [Abstract][Full Text] [Related]
24. Safety of allergen immunotherapy in North America from 2008-2017: Lessons learned from the ACAAI/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy.
Bernstein DI; Epstein TEG
Allergy Asthma Proc; 2020 Mar; 41(2):108-111. PubMed ID: 32122446
[TBL] [Abstract][Full Text] [Related]
25. The local and systemic side-effects of venom and inhaled-allergen subcutaneous immunotherapy.
Adamic K; Zidarn M; Bajrovic N; Erzen R; Kopac P; Music E
Wien Klin Wochenschr; 2009; 121(9-10):357-60. PubMed ID: 19562302
[TBL] [Abstract][Full Text] [Related]
26. Systemic Allergic Reactions and Anaphylaxis Associated with Allergen Immunotherapy.
Dhamija Y; Epstein TEG; Bernstein DI
Immunol Allergy Clin North Am; 2022 Feb; 42(1):105-119. PubMed ID: 34823741
[TBL] [Abstract][Full Text] [Related]
27. AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013-2017): Fatalities, Infections, Delayed Reactions, and Use of Epinephrine Autoinjectors.
Epstein TG; Liss GM; Berendts KM; Bernstein DI
J Allergy Clin Immunol Pract; 2019; 7(6):1996-2003.e1. PubMed ID: 30776526
[TBL] [Abstract][Full Text] [Related]
28. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment.
Calderón MA; Vidal C; Rodríguez Del Río P; Just J; Pfaar O; Tabar AI; Sánchez-Machín I; Bubel P; Borja J; Eberle P; Reiber R; Bouvier M; Lepelliez A; Klimek L; Demoly P;
Allergy; 2017 Mar; 72(3):462-472. PubMed ID: 27718250
[TBL] [Abstract][Full Text] [Related]
29. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study.
Cardona R; Lopez E; Beltrán J; Sánchez J
Allergol Immunopathol (Madr); 2014; 42(2):90-5. PubMed ID: 23265265
[TBL] [Abstract][Full Text] [Related]
30. [Safety of immunotherapy and skin tests with allergens in children younger than five years].
Rodríguez Pérez N; Ambriz Moreno Mde J
Rev Alerg Mex; 2006; 53(2):47-51. PubMed ID: 16884027
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review.
Erekosima N; Suarez-Cuervo C; Ramanathan M; Kim JM; Chelladurai Y; Segal JB; Lin SY
Laryngoscope; 2014 Mar; 124(3):616-27. PubMed ID: 23832632
[TBL] [Abstract][Full Text] [Related]
32. Subcutaneous Allergen-Specific Immunotherapy Is Safe in Pediatric Patients with Allergic Rhinitis.
Pavon-Romero GF; Larenas-Linnemann DE; Xochipa Ruiz KE; Ramirez-Jimenez F; Teran LM
Int Arch Allergy Immunol; 2021; 182(6):553-561. PubMed ID: 33611315
[TBL] [Abstract][Full Text] [Related]
33. Safety of subcutaneous allergen immunotherapy.
Bernstein DI; Epstein TG
Allergy Asthma Proc; 2022 Jul; 43(4):267-271. PubMed ID: 35818150
[TBL] [Abstract][Full Text] [Related]
34. Immediate adverse reactions to immunotherapy.
Can D; Demir E; Tanaç R; Gülen F; Yenigün A
J Investig Allergol Clin Immunol; 2003; 13(3):177-80. PubMed ID: 14635467
[TBL] [Abstract][Full Text] [Related]
35. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.
Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA
Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840
[TBL] [Abstract][Full Text] [Related]
36. Are large local reactions a marker for systemic reactions to subcutaneous immunotherapy in children?
Simsek IE; Aydogan M
Asian Pac J Allergy Immunol; 2022 Mar; 40(1):75-80. PubMed ID: 34246207
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy of immunotherapy in allergic rhinitis.
Oktemer T; Altıntoprak N; Muluk NB; Senturk M; Kar M; Bafaqeeh SA; Bellussi L; Passali D; Cingi C
Am J Rhinol Allergy; 2016 Sep; 30(5):4-7. PubMed ID: 29025463
[TBL] [Abstract][Full Text] [Related]
38. Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety.
Caminati M; Dama AR; Djuric I; Montagni M; Schiappoli M; Ridolo E; Senna G; Canonica GW
Expert Rev Clin Immunol; 2015 Feb; 11(2):233-45. PubMed ID: 25484197
[TBL] [Abstract][Full Text] [Related]
39. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, Year 3: what practices modify the risk of systemic reactions?
Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
Ann Allergy Asthma Immunol; 2013 Apr; 110(4):274-8, 278.e1. PubMed ID: 23535092
[TBL] [Abstract][Full Text] [Related]
40. Subcutaneous Immunotherapy Safety: Incidence per Surveys and Risk Factors.
Sánchez-Borges M; Bernstein DI; Calabria C
Immunol Allergy Clin North Am; 2020 Feb; 40(1):25-39. PubMed ID: 31761119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
